T. Rowe Price Associates
MRTX

T. Rowe Price Associates’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

T. Rowe Price Associates’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-38,061
Closed -$2.24M – 3009
2023
Q4 		$2.24M Sell
38,061
-2,394,968
-98% -$135M ﹤0.01% 1471
2023
Q3 		$106M Buy
2,433,029
+655,450
+37% +$23.4M 0.02% 507
2023
Q2 		$64.2M Buy
1,777,579
+6,638
+0.4% +$273K 0.01% 631
2023
Q1 		$65.8M Buy
1,770,941
+354,213
+25% +$15.9M 0.01% 608
2022
Q4 		$64.2M Buy
1,416,728
+273,973
+24% +$17.7M 0.01% 594
2022
Q3 		$79.8M Buy
1,142,755
+91,225
+9% +$6.75M 0.01% 530
2022
Q2 		$70.6M Sell
1,051,530
-592,686
-36% -$37.7M 0.01% 767
2022
Q1 		$135M Sell
1,644,216
-530,583
-24% -$54.3M 0.01% 637
2021
Q4 		$319M Buy
2,174,799
+60,589
+3% +$9.41M 0.03% 440
2021
Q3 		$374M Buy
2,114,210
+192,431
+10% +$31M 0.04% 399
2021
Q2 		$310M Buy
1,921,779
+389,279
+25% +$62.5M 0.03% 450
2021
Q1 		$263M Sell
1,532,500
-26,916
-2% -$5.33M 0.03% 477
2020
Q4 		$343M Buy
1,559,416
+248,154
+19% +$53.6M 0.04% 403
2020
Q3 		$218M Buy
1,311,262
+2,410
+0.2% +$330K 0.03% 466
2020
Q2 		$149M Buy
1,308,852
+21,207
+2% +$2.06M 0.02% 538
2020
Q1 		$99M Sell
1,287,645
-97,734
-7% -$8.77M 0.02% 577
2019
Q4 		$179M Buy
1,385,379
+48,815
+4% +$4.71M 0.02% 505
2019
Q3 		$104M Buy
1,336,564
+130,420
+11% +$12.2M 0.01% 625
2019
Q2 		$124M Buy
1,206,144
+388,516
+48% +$30.2M 0.02% 591
2019
Q1 		$59.9M Buy
817,628
+488,468
+148% +$33.2M 0.01% 801
2018
Q4 		$14M Buy
329,160
+1,136
+0.3% +$45.3K ﹤0.01% 1250
2018
Q3 		$15.4M Buy
328,024
+115,559
+54% +$6.43M ﹤0.01% 1295
2018
Q2 		$10.5M Buy
212,465
+26,145
+14% +$987K ﹤0.01% 1337
2018
Q1 		$5.72M Buy
+186,320
New +$5.17M ﹤0.01% 1416

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

T. Rowe Price Associates's MRTX Position: Q1 2024 in Review

T. Rowe Price Associates sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 38,061 shares — an estimated $2.24M sold.

T. Rowe Price Associates first reported a position in MRTX in Q1 2018 and held it in 24 quarters. The position peaked at $374M in Q3 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • T. Rowe Price Associates reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 38,061 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.24M.
  • T. Rowe Price Associates first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2018 and held it in 24 quarters.
  • T. Rowe Price Associates's Mirati Therapeutics, Inc. Common Stock position peaked at $374M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on T. Rowe Price Associates's 13F filing for Q1 2024, filed 15 May 2024.